Contrasting Cleveland BioLabs (CBLI) and Asterias Biotherapeutics (AST)

Cleveland BioLabs (NASDAQ: CBLI) and Asterias Biotherapeutics (NYSE:AST) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability and analyst recommendations.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Cleveland BioLabs and Asterias Biotherapeutics, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cleveland BioLabs 0 0 0 0 N/A
Asterias Biotherapeutics 0 0 2 0 3.00

Asterias Biotherapeutics has a consensus target price of $12.00, indicating a potential upside of 269.23%. Given Asterias Biotherapeutics’ higher probable upside, analysts clearly believe Asterias Biotherapeutics is more favorable than Cleveland BioLabs.


This table compares Cleveland BioLabs and Asterias Biotherapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cleveland BioLabs -253.09% -61.18% -49.90%
Asterias Biotherapeutics -2,762.03% -86.25% -66.19%

Institutional & Insider Ownership

4.6% of Cleveland BioLabs shares are owned by institutional investors. 2.4% of Cleveland BioLabs shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Cleveland BioLabs and Asterias Biotherapeutics’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Cleveland BioLabs $2.91 million 11.24 -$5.71 million ($0.66) -4.39
Asterias Biotherapeutics $6.15 million 26.41 -$29.79 million N/A N/A

Cleveland BioLabs has higher revenue, but lower earnings than Asterias Biotherapeutics.


Cleveland BioLabs beats Asterias Biotherapeutics on 6 of the 10 factors compared between the two stocks.

About Cleveland BioLabs

Cleveland BioLabs, Inc. (CBLI) is a biopharmaceutical company. The Company is engaged in developing approaches to activate the immune system and address serious medical needs. Its platform of Toll-like immune receptor activators has applications in mitigation of radiation injury and immuno-oncology. Its advanced product candidate is Entolimod, an immuno-stimulatory agent, which it is developing as a radiation countermeasure and an immunotherapy for oncology and other indications. Its other products include CBLB612, Mobilan and CBL0137. CBLB612 is a compound based upon a natural activator of another tissue-specific component of the innate immune system, the toll-like receptor 2 (TLR2)/ toll-like receptor 6 (TLR6) heterodimeric receptor. Mobilan is a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. CBL0137 is a small molecule with a multi-targeted mechanism of action that may be useful for the treatment of various types of cancer.

About Asterias Biotherapeutics

Asterias Biotherapeutics, Inc. is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients’ immune systems to attack their tumors. The second is pluripotent stem cell platform. Pluripotent cells are a type of stem cell capable of becoming all of the cell types in the human body. From its immunotherapy platform, the Company is developing over two programs. AST-VAC1 (telomerase loaded, autologous dendritic cells), which allows patient’s own cells to recognize and fight cancer cells in acute myelogenous leukemia (AML). Together with Cancer Research United Kingdom (CRUK), it is developing AST-VAC2 (telomerase loaded, -allogeneic dendritic cells), -derived from pluripotent stem cells. From its pluripotent stem cell platform, it is developing AST-OPC1, oligodendrocyte progenitor cells.

Receive News & Ratings for Cleveland BioLabs Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cleveland BioLabs Inc. and related companies with's FREE daily email newsletter.

Leave a Reply